LEXX vs CLPS Comparison

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

CLPS Inc is a holding company. The company through its subsidiaries provides information technology consulting and solutions institutions in the banking, insurance, and financial sectors, both in China and globally. Its products are Risk Control Platform, Transaction Acquiring Platform, Debt Collection Platform, Virtual Bank Training Platform, Credit Card System, and other related products. The company generates its revenue from IT consulting services, Customized IT solution services, and others. Generating the majority of its revenue from the IT consulting service.